InterMune Inc.'s idiopathic pulmonary fibrosis (IPF) drug pirfenidone still faces some regulatory hurdles in the U.S., but the Brisbane, Calif.-based company is set to roll out its commercialization force in Europe this fall following official marketing authorization of pirfenidone, branded Esbriet, in mild to moderate IPF.